LyphoMed Inc said it hastentatively agreed to form a joint venture with privately-heldNovopharm Ltd of Canada whereby each will market the other'sdrug in their home country.    LyphoMed will sell Novopharm's oral pharmaceutical drugs inthe U.S. and Novopharm will sell Lyphomed's injectablepharmaceutical drugs in Canada, it said.    The joint venture gives LyphoMed entry into the hospitaland retail oral pharmaceutical market with Novopharm's productline. Novopharm in turn will strengthen its position in theCanadian hospital market using LyphoMed's injectable products.    The first product to be marketed will be cephalexinmonohydrate, now marketed by Eli Lilly Co &lt;LLY> as Keflex, aproduct whose patent expires in April. Keflex is an antibioticwith a current market in excess of 250 mln dlrs. It will bemade by Novopharm in Canada, sold to the new joint venture, anddistributed by LyphoMed in the U.S., it said. Reuter&#3;